Treatment of serous macular detachment associated with circumscribed choroidal hemangioma

Hee Jung Kwon, Min Kim, Christopher Seungkyu Lee, Sungchul Lee

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

• PURPOSE: To evaluate the effects of transpupillary thermotherapy and intravitreal bevacizumab injection on serous macular detachment and cystoid macular edema (CME) associated with circumscribed choroidal hemangioma. • DESIGN: Retrospective, interventional case series. • METHODS: We reviewed the records of 12 patients with circumscribed choroidal hemangioma treated with transpupillary thermotherapy and/or intravitreal injection of bevacizumab. We assessed changes in best-corrected visual acuity (BCVA), central foveal thickness by optical coherence tomography, and resolution of serous macular detachment and CME. • RESULTS: Six of 8 patients treated with transpupillary thermotherapy showed complete resolution of serous macular detachment and CME and the median minimal angle of resolution (logMAR) BCVA improved from 0.85 to 0.35 (P = .026). Among these 6 patients, 1 had no recurrence for 86 months and 5 had sustained resolution of serous macular detachment for a mean duration of 32.8 months before recurrence. Among the 9 patients treated with bevacizumab (including 5 patients who had transpupillary thermotherapy as a primary treatment), 5 showed resolution of serous macular detachment and the median logMAR BCVA improved from 0.7 to 0.5 (P = .042). Among these 5 patients, 3 had sustained resolution for a mean duration of 5.7 months and 2 showed recurrent serous macular detachment after 3 and 12 months. • CONCLUSION: Transpupillary thermotherapy and intravitreal bevacizumab appear effective in the management of symptomatic circumscribed choroidal hemangioma, although recurrence of serous macular detachment and CME developed after long-term follow-up of transpupillary thermotherapy, and the duration of treatment effectiveness appears to be short with bevacizumab.

Original languageEnglish
Pages (from-to)137-145.e1
JournalAmerican Journal of Ophthalmology
Volume154
Issue number1
DOIs
Publication statusPublished - 2012 Jan 1

Fingerprint

Induced Hyperthermia
Hemangioma
Macular Edema
Visual Acuity
Intravitreal Injections
Recurrence
Therapeutics
Optical Coherence Tomography
Bevacizumab

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Kwon, Hee Jung ; Kim, Min ; Lee, Christopher Seungkyu ; Lee, Sungchul. / Treatment of serous macular detachment associated with circumscribed choroidal hemangioma. In: American Journal of Ophthalmology. 2012 ; Vol. 154, No. 1. pp. 137-145.e1.
@article{043a4eb142a64367a89f8e77e2f332b0,
title = "Treatment of serous macular detachment associated with circumscribed choroidal hemangioma",
abstract = "• PURPOSE: To evaluate the effects of transpupillary thermotherapy and intravitreal bevacizumab injection on serous macular detachment and cystoid macular edema (CME) associated with circumscribed choroidal hemangioma. • DESIGN: Retrospective, interventional case series. • METHODS: We reviewed the records of 12 patients with circumscribed choroidal hemangioma treated with transpupillary thermotherapy and/or intravitreal injection of bevacizumab. We assessed changes in best-corrected visual acuity (BCVA), central foveal thickness by optical coherence tomography, and resolution of serous macular detachment and CME. • RESULTS: Six of 8 patients treated with transpupillary thermotherapy showed complete resolution of serous macular detachment and CME and the median minimal angle of resolution (logMAR) BCVA improved from 0.85 to 0.35 (P = .026). Among these 6 patients, 1 had no recurrence for 86 months and 5 had sustained resolution of serous macular detachment for a mean duration of 32.8 months before recurrence. Among the 9 patients treated with bevacizumab (including 5 patients who had transpupillary thermotherapy as a primary treatment), 5 showed resolution of serous macular detachment and the median logMAR BCVA improved from 0.7 to 0.5 (P = .042). Among these 5 patients, 3 had sustained resolution for a mean duration of 5.7 months and 2 showed recurrent serous macular detachment after 3 and 12 months. • CONCLUSION: Transpupillary thermotherapy and intravitreal bevacizumab appear effective in the management of symptomatic circumscribed choroidal hemangioma, although recurrence of serous macular detachment and CME developed after long-term follow-up of transpupillary thermotherapy, and the duration of treatment effectiveness appears to be short with bevacizumab.",
author = "Kwon, {Hee Jung} and Min Kim and Lee, {Christopher Seungkyu} and Sungchul Lee",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/j.ajo.2012.01.007",
language = "English",
volume = "154",
pages = "137--145.e1",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "1",

}

Treatment of serous macular detachment associated with circumscribed choroidal hemangioma. / Kwon, Hee Jung; Kim, Min; Lee, Christopher Seungkyu; Lee, Sungchul.

In: American Journal of Ophthalmology, Vol. 154, No. 1, 01.01.2012, p. 137-145.e1.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of serous macular detachment associated with circumscribed choroidal hemangioma

AU - Kwon, Hee Jung

AU - Kim, Min

AU - Lee, Christopher Seungkyu

AU - Lee, Sungchul

PY - 2012/1/1

Y1 - 2012/1/1

N2 - • PURPOSE: To evaluate the effects of transpupillary thermotherapy and intravitreal bevacizumab injection on serous macular detachment and cystoid macular edema (CME) associated with circumscribed choroidal hemangioma. • DESIGN: Retrospective, interventional case series. • METHODS: We reviewed the records of 12 patients with circumscribed choroidal hemangioma treated with transpupillary thermotherapy and/or intravitreal injection of bevacizumab. We assessed changes in best-corrected visual acuity (BCVA), central foveal thickness by optical coherence tomography, and resolution of serous macular detachment and CME. • RESULTS: Six of 8 patients treated with transpupillary thermotherapy showed complete resolution of serous macular detachment and CME and the median minimal angle of resolution (logMAR) BCVA improved from 0.85 to 0.35 (P = .026). Among these 6 patients, 1 had no recurrence for 86 months and 5 had sustained resolution of serous macular detachment for a mean duration of 32.8 months before recurrence. Among the 9 patients treated with bevacizumab (including 5 patients who had transpupillary thermotherapy as a primary treatment), 5 showed resolution of serous macular detachment and the median logMAR BCVA improved from 0.7 to 0.5 (P = .042). Among these 5 patients, 3 had sustained resolution for a mean duration of 5.7 months and 2 showed recurrent serous macular detachment after 3 and 12 months. • CONCLUSION: Transpupillary thermotherapy and intravitreal bevacizumab appear effective in the management of symptomatic circumscribed choroidal hemangioma, although recurrence of serous macular detachment and CME developed after long-term follow-up of transpupillary thermotherapy, and the duration of treatment effectiveness appears to be short with bevacizumab.

AB - • PURPOSE: To evaluate the effects of transpupillary thermotherapy and intravitreal bevacizumab injection on serous macular detachment and cystoid macular edema (CME) associated with circumscribed choroidal hemangioma. • DESIGN: Retrospective, interventional case series. • METHODS: We reviewed the records of 12 patients with circumscribed choroidal hemangioma treated with transpupillary thermotherapy and/or intravitreal injection of bevacizumab. We assessed changes in best-corrected visual acuity (BCVA), central foveal thickness by optical coherence tomography, and resolution of serous macular detachment and CME. • RESULTS: Six of 8 patients treated with transpupillary thermotherapy showed complete resolution of serous macular detachment and CME and the median minimal angle of resolution (logMAR) BCVA improved from 0.85 to 0.35 (P = .026). Among these 6 patients, 1 had no recurrence for 86 months and 5 had sustained resolution of serous macular detachment for a mean duration of 32.8 months before recurrence. Among the 9 patients treated with bevacizumab (including 5 patients who had transpupillary thermotherapy as a primary treatment), 5 showed resolution of serous macular detachment and the median logMAR BCVA improved from 0.7 to 0.5 (P = .042). Among these 5 patients, 3 had sustained resolution for a mean duration of 5.7 months and 2 showed recurrent serous macular detachment after 3 and 12 months. • CONCLUSION: Transpupillary thermotherapy and intravitreal bevacizumab appear effective in the management of symptomatic circumscribed choroidal hemangioma, although recurrence of serous macular detachment and CME developed after long-term follow-up of transpupillary thermotherapy, and the duration of treatment effectiveness appears to be short with bevacizumab.

UR - http://www.scopus.com/inward/record.url?scp=84862771486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862771486&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2012.01.007

DO - 10.1016/j.ajo.2012.01.007

M3 - Article

C2 - 22465363

AN - SCOPUS:84862771486

VL - 154

SP - 137-145.e1

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 1

ER -